07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd.'s CEO is building his company along lines...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

APL-130277: Phase I started

Cynapsus disclosed in its 3Q12 earnings that it began the placebo-controlled, crossover Phase I CTH-103 trial to compare multiple doses of sublingual APL-130277 vs. subcutaneous apomorphine in healthy volunteers. Cynapsus Therapeutics Inc. (TSX:CTH), Toronto, Ontario...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Kyowa Hakko Kirin sales and marketing update

Kyowa launched Apokyn apomorphine in Japan to treat Parkinson's disease (PD). Apokyn has Orphan Drug status in Japan. Kyowa has rights to the apomorphine hydrochloride injection in Japan and part of Asia from the...
07:00 , May 7, 2012 |  BioCentury  |  Finance

BG-12 deal keeps on giving

The former shareholders of Fumapharm AG could be looking forward to more than $2.5 billion in milestones if sales for multiple sclerosis treatment BG-12 from Biogen Idec Inc. live up to Wall Street expectations. Last...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Apokyn apomorphine hydrochloride regulatory update

Japan's Ministry of Health, Labor and Welfare approved an NDA from Kyowa for 30 mg subcutaneous Apokyn apomorphine to treat Parkinson's disease (PD). Apokyn has Orphan Drug designation in Japan. Kyowa has rights to the...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

APL-130277: Phase I data

Top-line data from a placebo-controlled Phase I trial in 15 healthy volunteers showed that a majority of patients receiving sublingual 3 mg APL-130277 achieved maximum plasma concentrations within 20 minutes and led to a mean...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Ipsen, Vernalis deal

Vernalis received $1.9 million as the final milestone payment from Ipsen under a 2008 deal in which Ipsen acquired Vernalis' U.S. commercial operations subsidiary and U.S. rights to Vernalis' Apokyn apomorphine. The payment brings...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Britannia, Ipsen sales and marketing update

Britannia acquired North American commercialization rights from Ipsen for Apokyn apomorphine to treat "off" episodes associated with Parkinson's disease (PD). Ipsen said that Britannia will pay $10 million under the deal. Apokyn's 2010 sales...
08:00 , Mar 8, 2010 |  BioCentury  |  Finance

EPS Watch

EPS Watch Company 4Q09 EPS est 4Q09 EPS actual Outcome Growth from 4Q08 3/5 cls Wk chg %...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Ipsen, Vernalis deal

Vernalis will receive a $700,000 milestone payment from Ipsen under a 2008 deal in which Ipsen acquired Vernalis' U.S. subsidiary and U.S. rights to Vernalis' Apokyn apomorphine. The payment was triggered by an undisclosed...